For ICD definition

For ICD. For Collaborator (if separate from above): Division Director, Division of Technology Development and Transfer NIH Office of Technology Transfer 0000 Xxxxxxxxx Xxxxxxxxx, Xxxxx 000 Rockville, Maryland 00000-0000 Tel: 000-000-0000 Fax: 000-000-0000 Delivery of Materials Identified In Appendix B (if any) For ICD: For Collaborator: ICD Project Officer for Extramural Investigators Name: Branch: Address: Telephone: SUMMARY PAGE EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, RELEASE THIS SUMMARY PAGE TO THE PUBLIC. TITLE OF CRADA: PHS [ICD] Component: ICD CRADA Principal Investigator: Collaborator: Collaborator CRADA Principal Investigator: Term of CRADA: ( ) years from the Effective Date ABSTRACT OF THE RESEARCH PLAN: Appendix C CTEP Exceptions or Modifications to this CRADA (6/26/06) Appendix C Exceptions or Modifications to this CRADA Additions and deletions within Articles of the extramural clinical trial CRADA appear as underline and strikeout, respectively.
Sample 1Sample 2
For ICD. For Collaborator (if separate from above): Division Director, Division of Technology (same as above) Development and Transfer NIH Office of Technology Transfer 0000 Xxxxxxxxx Xxxxxxxxx, Xxxxx 000 Xxxxxxxxx, Xxxxxxxx 00000-0000 Tel: 000-000-0000 Fax: 000-000-0000 Delivery of Materials Identified In Appendix B (if any) For ICD: For Collaborator (if separate from above): Xxxxxx X. Xxxxxxxxx, M.D., Ph.D. (same as above) Surgery Branch, NCI 00 Xxxxxx Xxxxx, XXX 0000 Xxxx. 00, CRC Room 3-3940 Xxxxxxxx, XX 00000-0000 Tel. 000-000-0000 Fax: 000-000-0000 PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH SUMMARY PAGE EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, RELEASE THIS SUMMARY PAGE TO THE PUBLIC. TITLE OF CRADA: Cooperative Research and Development Agreement for the Development of NCI Proprietary Peripheral Blood Autologous T Cell Therapies Using Genetically Modified Peripheral. Blood Lymphocytes That Express NCI Proprietary T Cell Receptors and/or Chimeric Antigen Receptors for Use in the Immunotherapy for Patients with Metastatic Cancer, Utilizing the Expertise of Kite Pharma in Development and Manufacturing of Cancer Immunotherapies PHS [ICD] Component: National Cancer Institute (NCI) ICD CRADA Principal Investigator: Xxxxxx X Xxxxxxxxx, M.D., PhD. Collaborator: Kite Pharma, Inc. Collaborator CRADA Principal Investigator: Xxx Xxxxxxxxxx, Ph.D. Term of CRADA: Five (5) years from the Effective Date ABSTRACT OF THE RESEARCH PLAN: […***…]. ***Confidential Treatment Requested PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 23 of 52 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH APPENDIX A RESEARCH PLAN Title of CRADA Cooperative Research and Development Agreement for the Development of NCI Proprietary Peripheral Blood Autologous T Cell Therapies Using Genetically Modified Peripheral Blood Lymphocytes That Express NCI Proprietary T Cell Receptors and/or Chimeric Antigen Receptors for Use in the Immunotherapy for Patients with Metastatic Cancer, Utilizing the Expertise of Kite Pharma in Development and Manufacturing of Cancer Immunotherapies NCI Principal Investigator Xxxxxx X. Xxxxxxxxx, M.D., Ph.D. Chief, Surgery Branch Center for Cancer Research (CCR) National Cancer Institute (NCI) Collaborator Principal Investigators Xxx Xxxxxxxxxx, Ph.D. President & Chief Execut...
Sample 1Sample 2
For ICD. For Collaborator (if separate from above): Division Director, Division of Technology Same as above Development and Transfer NIH Office of Technology Transfer 0000 Xxxxxxxxx Xxxxxxxxx, Xxxxx 000 Xxxxxxxxx, Xxxxxxxx 00000-0000 Tel: 000-000-0000 Fax: 000-000-0000 Delivery of Materials Identified In Appendix B (if any)
Sample 1Sample 2

Examples of For ICD in a sentence

  • Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(2), (4), (5) and (6) and 230.406 CONTACTS INFORMATION PAGE CRADA Notices For ICD: For Collaborator: Technology Transfer Center [***] National Cancer Institute President and CEO 0000 Xxxxxxxxx Xxxx., Xxxxx 000 BN ImmunoTherapeutics, Inc.

  • No. MODEL ADOPTED June 18, 2009 Page 21 of 52 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH CONTACTS INFORMATION PAGE CRADA Notices For ICD: For Collaborator: Technology Transfer Center Xxx Xxxxxxxxxx, Ph.D. 0000 Xxxxxxxxx Xxxx., Xxxxx 000 President & Chief Executive Officer Rockville, MD 20852 Kite Pharma, Inc.

  • Xxxxx 000 Xxx Xxxxx, XX 00000 Xxxxxxxxx, XX 00000 Tel: 000-000-0000 Tel: 000-000-0000 Fax: 000-000-0000 Fax: 000-000-0000 Patenting and Licensing For ICD: For Collaborator (if separate from above): Division Director, Division of Technology Xxxxx Xxxxx Development and Transfer Tracon Pharmaceuticals, Inc.

  • Xxxxxxxxx, XX 00000-0000 0000 Xxxxxx Xxxxxx Phone: 000-000-0000 Xxxxxxxx Xxxx, XX 00000 Fax: 000-000-0000 Tel: [***] Fax: [***] Patenting and Licensing For ICD: For Collaborator (if separate from above): Division Director, Division of Technology [***] Development and Transfer President and CEO NIH Office of Technology Transfer BN ImmunoTherapeutics, Inc.

  • No.02663 MODEL ADOPTED June 18, 2009 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH CONTACTS INFORMATION PAGE CRADA Notices For ICD: Technology Transfer Center 0000 Xxxxxxxxx Xxxx., Xxxxx 000 Xxxxxxxxx, XX 00000 Tel.

  • No.02661 MODEL ADOPTED June 18, 2009 TRACON CONFIDENTIAL CONTACTS INFORMATION PAGE CRADA Notices For ICD: For Collaborator: Director Xxxxx Xxxxx Technology Transfer Center Tracon Pharmaceuticals, Inc.

  • Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(2), (4), (5) and (6) and 230.406 CONTACTS INFORMATION PAGE CRADA Notices For ICD: For Collaborator: Technology Transfer Center [***] National Cancer institute President and CEO 0000 Xxxxxxxxx Xxxx., Xxxxx 000 BN ImmunoTherapeutics, Inc.

  • No. _______ MODEL ADOPTED June 18, 2009 Page 21 of 55 Public Health Service Cooperative Research And Development Agreement For Intramural-PHS Clinical Research CONTACTS INFORMATION PAGE CRADA Notices For ICD: Technology Transfer Center 0000 Xxxxxxxxx Xxxx., Xxxxx 000 Xxxxxxxxx, XX 00000 Tel.

  • No. ______ MODEL ADOPTED June 18, 2009 CONTACTS INFORMATION PAGE CRADA Notices For ICD: For Collaborator: Technology Transfer Center, NCI Genesis Biopharma, Inc.

  • No. 02734 MODEL ADOPTED June 18, 2009 CONTACTS INFORMATION PAGE CRADA Notices For ICD: For Collaborator: Technology Transfer Center, NCI Genesis Biopharma, Inc.


More Definitions of For ICD

For ICD. For Collaborator: Technology Transfer Center Chief Medical Officer National Cancer Institute Attn: Xx. Xxxxx Xxxxxxx Rockville, MD 20852 1450 Infinite Dr. Phone: 000-000-0000 Xxxxxxxxxx, XX 00000 Fax: 000-000-0000 Phone: 000-000-0000 Fax: 000-000-0000 Patenting and Licensing
Sample 1
For ICD. For Collaborator (if separate from above): Division Director, Division of Technology Development and Transfer Chief Medical Officer NIH Office of Technology Transfer Attn: Xxxxxxx Xxxx 0000 Xxxxxxxxx Xxxxxxxxx, Xxxxx 000 1450 Infinite Dr. Rockville, Maryland 20852-3804 Xxxxxxxxxx, XX 00000 Tel: 000-000-0000 Phone: 000-000-0000 Fax: 000-000-0000 Fax: 000-000-0000 Delivery of Materials Identified In Appendix B (if any)
Sample 1
For ICD. For Collaborator: Xx. Xxxxxxxxx Xxxxxx N.A. Xxxx 00 Xxxx 0X000 00 Xxxxxx Xxxxx Xxxxxxxx, XX 00000 SUMMARY PAGE EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION. RELEASE THIS SUMMARY PAGE TO THE PUBLIC. TITLE OF CRADA: Identification of agents regulating Nuclear Receptor Corepressor (N-CoR) pathway for glioma tumor cell differentiation PHS[ICD] Component: National Institute of Neurological Disorders and Stroke ICD Principal Investigator: Xx. Xxxxxx Xxxxxxxx ICD Co-Principal Investigator: Xx. Xxxxxxxxx Xxxxxx Collaborator: Lixte, Inc. Collaborator Principal Investigator: Xx. Xxxx X.Kovach TERM OF CRADA: 2 (Two) years from the Effective Date ABSTRACT OF THE RESEARCH PLAN: The National Institute of Neurological Disorders and Stroke (“NINDS”) in Bethesda, Maryland, and Lixte, Inc. will collaborate in the identification and evaluation of agents that target the Nuclear Receptor CoRepressor (N-CoR) pathway for glioma tumor cell differentiation. NINDS and Lixte, Inc. will also conduct research to determine if expression of N-CoR correlates with prognosis in glioma patients. PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT APPENDIX A RESEARCH PLAN Scope of this CRADA The subject of this CRADA is limited to identifying agents that act synergistically with retinoic acid (RA) or okadaic acid to inhibit proliferation of Glioblastoma multiforme (GBM) cells and to determine if expression of Nuclear Receptor Corepressor (N-CoR) correlates with prognosis in glioma patients.
Sample 1
For ICD. For Collaborator: Xx. Xxxxxxxxx Xxxxxx N.A. Xxxx 00 Xxxx 0X000 00 Xxxxxx Xxxxx Xxxxxxxx, XX 00000 SUMMARY PAGE EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION. RELEASE THIS SUMMARY PAGE TO THE PUBLIC. TITLE OF CRADA: Identification of agents regulating Nuclear Receptor Corepressor (N-CoR) pathway for glioma tumor cell differentiation PHS[ICD] Component: National Institute of Neurological Disorders and Stroke ICD Principal Investigator: Xx. Xxxxxx Xxxxxxxx ICD Co-Principal Investigator: Xx. Xxxxxxxxx Xxxxxx Collaborator: Lixte, Inc. Collaborator Principal Investigator: Xx. Xxxx X.Kovach TERM OF CRADA: 2 (Two) years from the Effective Date SIGNATURE PAGE ACCEPTED AND AGREED TO FOR NINDS: /s/ Story Xxxxxx 10/19/06 Story Xxxxxx, Ph.D. Date Director, National Institute of Neurological Disorders and Stroke FOR COLLABORATOR: /s/ Xxxx X. Xxxxxx 10/26/06 Xx. Xxxx X. Kovach Date President, Lixte Biotechnology, Inc.
Sample 1

Related to For ICD

  • Embryo/fetus means the developing human organism from conception until the time of birth.

  • Embryo/fetus means the developing human organism from conception until the time of birth.

  • General anesthesia means a drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation. The ability to independently maintain ventilatory function is often impaired. Patients often require assistance in maintaining a patent airway, and positive pressure ventilation may be required because of depressed spontaneous ventilation or drug-induced depression of neuromuscular function. Cardiovascular function may be impaired.

  • Psychotherapy or "Therapy" means a goal directed process using generally accepted clinical approaches provided face-to-face by a qualified service provider with consumers in individual, group or family settings to promote positive emotional or behavioral change.

  • Cell means a single encased electrochemical unit containing one positive and one negative electrode which exhibits a voltage differential across its two terminals.

  • Disposable respirator means a respirator for which maintenance is not intended and that is designed to be discarded after excessive breathing resistance, sorbent exhaustion, physical damage, or end-of-service-life renders it unsuitable for use. Examples of this type of respirator are a disposable half-mask respirator or a disposable escape-only self-contained breathing apparatus (SCBA).

  • Positive pressure respirator means a respirator in which the pressure inside the respiratory inlet covering exceeds the ambient air pressure outside the respirator.

  • Physiotherapist means a person who is a) duly registered with the Supplementary Medical Professions Council of Hong Kong pursuant to the Supplementary Medical Professions Ordinance (Cap. 359 of the Laws of Hong Kong) or in relation to jurisdictions outside of Hong Kong, a body of equivalent standing; and b) legally authorised for practising physiotherapy in the locality where the treatment is provided to an Insured, but in no circumstance shall include the Insured, the Policyholder, an insurance intermediary or an employer, employee, Immediate Family Member or business partner(s) of the Policyholder and/or the Insured(s).

  • genocide means any of the following acts committed with intent to destroy, in whole or in part, a national, ethnical, racial or religious group, as such:

  • HCD means the California Department of Housing and Community Development.

  • BSP is the amount of the Bonus Severance Payment, before the deduction of applicable federal, state and local withholding taxes;

  • Preschooler means a child age two through four years old.

  • Embryo or "fetus" means the developing human organism from conception until time of birth.

  • Adolescent means a Medicaid patient 17 years or younger.

  • Behavioral therapy means interactive therapies derived from evidence-based research, including applied behavior analysis, which includes discrete trial training, pivotal response training, intensive intervention programs, and early intensive behavioral intervention.

  • Volunteers means GM or non-GM Canola plants, which have not been intentionally grown.

  • Therapeutic school means a residential group living facility:

  • UMDAP means the Uniform Method of Determining Ability to Pay and refers to the 2 method used for determining the annual Client liability for Mental Health Services received from the 3 COUNTY mental health system and is set by the State of California.

  • Check 21 means the Check Clearing for the 21st Century Act.

  • scientific research means any activity in the field of natural or applied science for the extension of knowledge;

  • Psychiatric nurse means a registered nurse who has

  • Chiropractor means an individual licensed under Chapter 4734. of the Revised Code to practice chiropractic.

  • Gene Therapy means the introduction of a nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit into a person for therapeutic purposes (i) by in vivo introduction for incorporation into cells of such person, or (ii) by ex vivo introduction into cells for transfer into a person.

  • Midwife means a midwife in good standing with the College of Midwives of Ontario;

  • Bioassay means the determination of kinds, quantities or concentrations and, in some cases, the locations of radioactive material in the human body, whether by direct measurement, in vivo counting, or by analysis and evaluation of materials excreted or removed from the human body. For purposes of these rules, “radiobioassay” is an equivalent term.

  • Dyslexia means a disorder of constitutional origin manifested by a difficulty in learning to read, write, or spell, despite conventional instruction, adequate intelligence, and sociocultural opportunity.